AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript
AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.
How this was made
The 30-second read
Why it matters
Traders can update models based on the reported Q4 revenue and segment mix, and incorporate the stated IDE approvals and active pivotal trial timelines into catalyst-driven expectations for FY2027.
Market read
The transcript provides actionable quarterly financial datapoints and catalyst updates (IDE approvals, pivotal trial activity, reimbursement/CPT code effectiveness) that can influence near-term positioning.
What to watch
Tariff absorption is cited as a headwind; also, the call references divested/discontinued product lines and pro forma metrics, which can complicate apples-to-apples comparisons.
Background
AngioDynamics held its fiscal 2026 fourth quarter and full-year earnings call, emphasizing Med Tech growth, profitability, and upcoming clinical/regulatory catalysts.
Ticker impact
AngioDynamics reports fiscal 2026 Q4 revenue of $86.6M (+8%) and details Med Tech platform mix, catalysts, and leadership transition into FY2027.
Moderate positive bias for the next few sessions as traders digest Q4 numbers and the stated FY2027 outlook/catalysts, with volatility around any guidance specifics not shown in the excerpt.
The article includes concrete Q4 and segment revenue figures plus new catalyst framing (IDE approvals and active pivotal trial). However, the excerpt cuts off before any explicit FY2027 guidance numbers, limiting conviction on magnitude.
Market effects
Reinforces investor appetite for interventional and cardiovascular med-tech platforms with clinical-data and reimbursement/CPT-code catalysts.
No clear regional-specific impact beyond U.S. reimbursement and Medicare coverage framework mentioned.
Mentions international adoption following CE mark approval, supporting cross-border demand expectations.
Counterpoint
Mechanical Thrombectomy shows mixed performance (AngioVac down YoY while AlphaVac up), and the excerpt does not confirm whether FY2027 guidance meaningfully offsets that variability.
Key entities
- companyAngioDynamics
Med-tech company reporting fiscal 2026 Q4 and full-year results and outlining FY2027 catalysts and CEO transition.
